ECM
DMAC icon

ExodusPoint Capital Management’s DiaMedica Therapeutics DMAC Stock Holding History

ExodusPoint Capital Management’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$406K Buy
+60,011
New +$476K ﹤0.01% 1240
2025
Q2 		– Sell
-13,343
Closed -$51K – 1578
2025
Q1 		$51K Buy
+13,343
New +$76.3K ﹤0.01% 1370
2021
Q1 		– Sell
-13,160
Closed -$133K – 2212
2020
Q4 		$133K Buy
+13,160
New +$72K ﹤0.01% 1799

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ExodusPoint Capital Management's DMAC Position: Q1 2026 in Review

ExodusPoint Capital Management opened a new position in DiaMedica Therapeutics (DMAC) in Q1 2026: 60,011 shares worth $406K. The stake represents ﹤0.01% of the portfolio and ranks #1240 among its holdings. This is a return to the name: ExodusPoint Capital Management previously reported a position in DMAC as recently as Q1 2025.

ExodusPoint Capital Management first reported a position in DMAC in Q4 2020 and has held it in 3 quarters since. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • ExodusPoint Capital Management held 60,011 shares of DiaMedica Therapeutics worth $406K as of Q1 2026.
  • DiaMedica Therapeutics was a new ExodusPoint Capital Management position in Q1 2026.
  • DiaMedica Therapeutics made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #1240 holding.
  • ExodusPoint Capital Management first reported a position in DiaMedica Therapeutics in Q4 2020 and has held it in 3 quarters since.
  • 98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.